Stifel's Head of Therapeutics Research Paul Matteis shares his take on biotech and discusses companies he covers that have been in the news
He discusses Biogen, Alnylam, Xenon, and Compass Pathways
Chapters
General sentiment - 0:25
Biogen - 2:00
Alnylam - 4:14
Xenon - 6:44
Compass Pathways - 8:23
Coverage brought to you by










.png)
